|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6277 USD | +3.41% |
|
+2.07% | -53.50% |
By Denny Jacob
Biora Therapeutics' investigational new drug application for moderate to severe ulcerative colitis treatment BT-600 was cleared by the Food and Drug Administration.
Ariella Kelman, chief medical officer of the biotech company, said Biora will complete activities required by the FDA and trial site prior to enrolling the first subject in its Phase 1 clinical trial in the U.S. in the coming weeks.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
11-30-23 1714ET
| 1st Jan change | Capi. | |
|---|---|---|
| -53.50% | 22.52M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
BIORA THERAPEUTICS, INC. 
